TABLE 1

Characteristics of subjects and individual estimates of their CYP2C8 turnover half-lives and FDCL24 values

Subject 5 was excluded from all pharmacokinetic analyses, because of failure to comply with the gemfibrozil dosing schedule in the 48-h interval study phase.

Subject No.AgeSexWeightBMICYP2C8 GenotypeSLCO1B1 GenotypeCYP2C8 t1/2FDCL24
yrkgkg/m2h%
121Male7322*1/*4*15/*1516.562.3
221Male8323*1/*1*15/*1516.664.4
322Female6425*1/*1*1A/*1A30.874.2
423Male8525*1/*1*1A/*1517.765.4
525Male9028*1/*3*5/*15
619Male8027*1/*1*1A/*1B27.263.9
722Female6420*1/*3*1B/*1520.572.5
820Male8723*1/*3*1A/*1B16.272.9
923Male6822*1/*1*1A/*1518.362.8
1025Male8526*1/*1*1A/*1A30.972.0
Mean ± S.D.22.1 ± 2.078 ± 1024 ± 2.521.6 ± 6.268.3 ± 4.9
  • BMI, body mass index; CYP2C8 t1/2, turnover half-life of CYP2C8; FDCL24, fractional decrement in the oral clearance of repaglinide when repaglinide was administered 24 h after the last dose of gemfibrozil, derived by nonlinear regression analysis as described under Materials and Methods.